ArticleClinical rheumatology2026
Qualitative analysis of COVID-19 experiences with testing and vaccination among people with systemic lupus erythematosus in the USA.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionPeople with systemic lupus erythematosus (SLE) have faced unique challenges during the COVID-19 pandemic. This study examines these experiences and identifies barriers and facilitators related to COVID-19 testing and vaccination among people with SLE.
methodsParticipants were 25 SLE patients seeking care in two large medical centers in the US South recruited between October 2022 and April 2023. Fifteen one-on-one interviews were conducted; three were with dyads and one was with a group of four people. Sessions were recorded using Zoom Video Communications, which were transcribed and analyzed according to the guidelines of thematic analysis with NVivo 12.
resultsEmerging themes were examined using the social-ecological framework and organized around the impact of COVID-19 and barriers and facilitators of testing and vaccination. Factors that facilitated testing included availability and convenience of home testing; barriers were unclear directions for home tests and lack of accuracy of tests, and lack of clarity about when to get tested. Fear of side effects was cited as a major barrier to vaccination. Healthcare communication about vaccine benefits, particularly in the context of being immunocompromised, were motivating factors.
conclusionInterventions may be implemented at multiple levels to address barriers to COVID-19 testing and vaccination among SLE patients. Clear and comprehensive guidelines for those with SLE, as well as efforts to enhance structural competency among providers, including a greater understanding of COVID-19 experiences in the context of SLE, may support protective behaviors in this patient population. Key Points • Accurate and up-to-date information from healthcare providers and other trusted sources that is tailored for SLE patients can facilitate testing and vaccination in response to novel infectious disease. • Many SLE patients displayed resilience and drew from sources of support in response to unique challenges during the COVID-19 pandemic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.